Down Syndrome Clinical Trial
Official title:
Cardiometabolic Risk and Obesity in Adolescents With Down Syndrome
The purpose of this research study is to determine which measures best capture cardiovascular
disease (CVD) risk and type 2 diabetes (T2DM) risk in children and adolescents with Down
syndrome (DS).
We hypothesize that DS is associated with worse cardiometabolic risk factors for a given body
mass index compared to controls. This difference arises at least in part, from increased fat
tissue.
DS affects 1 per 800 births and is one of the most common causes of developmental disability
in the US. Life expectancy for Down syndrome has increased significantly: estimated median
survival in the US in 1997 was 49 years. DS is associated with an increased risk for obesity,
with an estimated prevalence of 47-48% in adults and 30-50% in children with DS. Adolescents
with DS are more likely to have increased adiposity compared to unaffected peers and may be
at increased risk for obesity-related co-morbidities, such as type 2 diabetes and
cardiovascular disease. How one defines obesity in DS is not clear. Individuals with DS have
short stature and possibly increased adiposity, and the body mass index (BMI) used to define
obesity for otherwise healthy populations may not accurately depict body fatness or capture
cardiometabolic risk in DS.
Congenital heart disease (CHD) affects approximately 50% of individuals with DS; the National
Institutes of Health Heart Lung and Blood Institute (NHLBI) Working Group on Obesity and
Other Cardiovascular Risk Factors in Congenital Heart Disease highlighted the high prevalence
of obesity in the setting of CHD, and called for studies to identify obesity measures that
are more sensitive than BMI as well as studies of CVD risk prevention. Unfortunately,
clinicians caring for obese adolescents with DS with or without CHD have little scientific
evidence upon which to base guidance regarding cardiometabolic risk (CMR): data regarding CVD
risk and prevalence of pre-diabetes and T2DM in obese adolescents with DS are lacking.
The measure of body fatness which best predicts CMR in DS is not known. We plan to compare
BMI and other measures of body fatness in healthy controls and adolescents with DS to
determine which measures best capture CVD and/or T2DM risk. These data will equip medical
providers with the tools to better assess risk, initiate prevention measures, and guide
screening in adolescents with DS.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04854122 -
Blood Flow Regulation in Individuals With Down Syndrome - Training Study
|
N/A | |
| Completed |
NCT04020302 -
Self-Monitoring Shopping Intervention
|
N/A | |
| Recruiting |
NCT01950624 -
DS-Connect {TM}: The Down Syndrome Registry
|
||
| Completed |
NCT04751136 -
the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome
|
Phase 2 | |
| Completed |
NCT04767412 -
Inspiratory Muscle Training and Physical Fitness in Children With Down Syndrome Randomized Control Trial
|
N/A | |
| Not yet recruiting |
NCT04037579 -
Protocol for a Non-randomized Survey in Down Syndrome People Who Practice Sports. Self and Observers´ Perception.
|
||
| Completed |
NCT04536506 -
Bobath and Vojta Therapy for DS
|
N/A | |
| Completed |
NCT02882698 -
Performance Analysis in Down Syndrome on Mobile Phone
|
N/A | |
| Completed |
NCT01791725 -
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
|
Phase 2 | |
| Unknown status |
NCT01975545 -
Fluor Varnish With Silver Nanoparticles for Dental Remineralization in Patients With Trisomy 21
|
Phase 2 | |
| Completed |
NCT01808508 -
Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome
|
N/A | |
| Terminated |
NCT00754013 -
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10
|
Phase 3 | |
| Terminated |
NCT00754052 -
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17
|
Phase 3 | |
| Completed |
NCT01313325 -
Hippotherapy to Improve the Balance of Children With Movement Disorders
|
N/A | |
| Completed |
NCT01256112 -
Parent Supported Weight Reduction in Down Syndrome
|
N/A | |
| Completed |
NCT01594346 -
Multicenter Vitamin E Trial in Aging Persons With Down Syndrome
|
Phase 3 | |
| Completed |
NCT05343468 -
Life Skills Improved in Children With Down Syndrome After Using Assistive Technology
|
N/A | |
| Suspended |
NCT05755464 -
Evaluation of Patients With Down Syndrome Compliance to Dental Therapy
|
||
| Recruiting |
NCT04022460 -
Using Personal Mobile Technology to Identify Obstructive Sleep Apnea in Children With Down Syndrome (UPLOAD)
|
||
| Completed |
NCT04818437 -
Effect of Core Stability Exercises and Balance Training in Postural Control Among Down Syndrome
|
N/A |